Patient baseline characteristics (N = 33)
| Characteristic . | No. (%) of patients . | Value . |
|---|---|---|
| Sex | ||
| Male | 21 (64) | |
| Female | 12 (36) | |
| Age, y | ||
| Median | 71 | |
| Range | 60-88 | |
| 60-64 | 6 (18) | |
| 65-69 | 8 (24) | |
| ≥ 70 | 19 (58) | |
| ECOG performance status | ||
| 0 | 16 (49) | |
| 1 | 13 (39) | |
| 2 | 4 (12) | |
| AML type | ||
| De novo | 23 (70) | |
| Prior MDS | 8 (24) | |
| Treatment-related | 2 (6) | |
| Presenting WBC count (per microliter) | ||
| Median | 4200 | |
| Range | 600-44 000 | |
| < 10 000 | 24 (73) | |
| ≥ 10 000 | 9 (27) | |
| Presenting BM blast, % | ||
| Median | 53% | |
| Range | 21%-97% | |
| Undefined | 2 (6) | |
| 20-30 | 8 (24) | |
| 31-50 | 7 (21) | |
| > 50 | 16 (49) | |
| Presenting PB blast count (per microliter) | ||
| Median | 140 | |
| Range | 0-22 770 | |
| < 1000 | 20 (61) | |
| 1000-10 000 | 9 (27) | |
| > 10 000 | 4 (12) | |
| Cytogenetic risk category | ||
| Intermediate | 18 (55) | |
| Unfavorable | 13 (39) | |
| Unknown | 2 (6) |
| Characteristic . | No. (%) of patients . | Value . |
|---|---|---|
| Sex | ||
| Male | 21 (64) | |
| Female | 12 (36) | |
| Age, y | ||
| Median | 71 | |
| Range | 60-88 | |
| 60-64 | 6 (18) | |
| 65-69 | 8 (24) | |
| ≥ 70 | 19 (58) | |
| ECOG performance status | ||
| 0 | 16 (49) | |
| 1 | 13 (39) | |
| 2 | 4 (12) | |
| AML type | ||
| De novo | 23 (70) | |
| Prior MDS | 8 (24) | |
| Treatment-related | 2 (6) | |
| Presenting WBC count (per microliter) | ||
| Median | 4200 | |
| Range | 600-44 000 | |
| < 10 000 | 24 (73) | |
| ≥ 10 000 | 9 (27) | |
| Presenting BM blast, % | ||
| Median | 53% | |
| Range | 21%-97% | |
| Undefined | 2 (6) | |
| 20-30 | 8 (24) | |
| 31-50 | 7 (21) | |
| > 50 | 16 (49) | |
| Presenting PB blast count (per microliter) | ||
| Median | 140 | |
| Range | 0-22 770 | |
| < 1000 | 20 (61) | |
| 1000-10 000 | 9 (27) | |
| > 10 000 | 4 (12) | |
| Cytogenetic risk category | ||
| Intermediate | 18 (55) | |
| Unfavorable | 13 (39) | |
| Unknown | 2 (6) |
ECOG indicates Eastern Cooperative Oncology Group.